The polymorphic variants DRD2 rs1800497 and ABCB1 3435C>T are associated with antipsychotic safety parameters in adolescents with an acute psychotic episode: the results of a pilot study
Children and adolescents are more likely than adults to experience adverse side effects when taking antipsychotics. Pharmacogenetic testing allows one to more accurately choose the initial dose of a drug. The genes of pharmacokinetic factors have been shown to be of high prognostic value for the saf...
Main Authors: | , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA-PRESS LLC
2020-10-01
|
Series: | Nevrologiâ, Nejropsihiatriâ, Psihosomatika |
Subjects: | |
Online Access: | https://nnp.ima-press.net/nnp/article/view/1324 |
id |
doaj-7997357ca57c4d20be84eae91f17b21f |
---|---|
record_format |
Article |
spelling |
doaj-7997357ca57c4d20be84eae91f17b21f2021-07-29T08:58:41ZrusIMA-PRESS LLCNevrologiâ, Nejropsihiatriâ, Psihosomatika2074-27112310-13422020-10-01125243110.14412/2074-2711-2020-5-24-31985The polymorphic variants DRD2 rs1800497 and ABCB1 3435C>T are associated with antipsychotic safety parameters in adolescents with an acute psychotic episode: the results of a pilot studyD. V. Ivashchenko0S. Z. Khoang1M. Kh. Tazagulova2B. V. Makhmudova3N. I. Buromskaya4P. V. Shimanov5R. V. Deitch6I. V. Dorina7M. I. Nastovich8K. A. Akmalova9A. A. Kachanova10E. A. Grishina11L. M. Savchenko12Yu. S. Shevchenko13D. A. Sychev14Russian Medical Academy of Continuing Professional Education, Ministry of Health of RussiaI.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of RussiaRussian Medical Academy of Continuing Professional Education, Ministry of Health of RussiaM.V. Lomonosov Moscow State UniversityG.E. Sukhareva Research and Practical Center for Mental Health of Children and Adolescents, Moscow Healthcare DepartmentG.E. Sukhareva Research and Practical Center for Mental Health of Children and Adolescents, Moscow Healthcare DepartmentG.E. Sukhareva Research and Practical Center for Mental Health of Children and Adolescents, Moscow Healthcare DepartmentG.E. Sukhareva Research and Practical Center for Mental Health of Children and Adolescents, Moscow Healthcare DepartmentG.E. Sukhareva Research and Practical Center for Mental Health of Children and Adolescents, Moscow Healthcare DepartmentRussian Medical Academy of Continuing Professional Education, Ministry of Health of RussiaRussian Medical Academy of Continuing Professional Education, Ministry of Health of RussiaRussian Medical Academy of Continuing Professional Education, Ministry of Health of RussiaRussian Medical Academy of Continuing Professional Education, Ministry of Health of RussiaRussian Medical Academy of Continuing Professional Education, Ministry of Health of RussiaRussian Medical Academy of Continuing Professional Education, Ministry of Health of RussiaChildren and adolescents are more likely than adults to experience adverse side effects when taking antipsychotics. Pharmacogenetic testing allows one to more accurately choose the initial dose of a drug. The genes of pharmacokinetic factors have been shown to be of high prognostic value for the safety of antipsychotics in adults.Patients and methods. The study enrolled 36 adolescents (58.3% male) (mean age, 14.83±1.84 years). All the patients took an antipsychotic. The follow-up lasted 28 days. On 14 and 28 days of treatment, its efficiency and safety were evaluated using the Children's Global Assessment Scale (CGAS), the Positive and Negative Syndrome Scale (PANSS), the Udvalg for Kliniske Undersњgelser Side Effects Rating Scale (UKU-SERS), the Simpson-Angus Scale (SAS), and the Barnes Akathisia Rating Scale (BARS). The patients were genotyped for CYP3A4*22, CYP3A5*3, CYP2D6*4, *9, *10, ABCB1 1236C>T, 2677G>T/A, 3435C>T, DRD2 rs1800497, DRD4 rs1800955, and HTR2A rs6313.Results and discussion. The decrease in the mean score of the PANSS subscale “Productive symptoms” was more pronounced in carriers of the DRD2 rs1800497 polymorphic variant (-6.5 [-10.25; -3.75] vs -3 [-6.5; -2 ] on 14 day (p=0.028) and (-11 [-13; -9.5] vs -5 [-9; -3.5] on 28 day (p=0.001) compared to baseline. The carriage of ABCB1 3435CT+TT was associated with worse tolerance to pharmacotherapy on 14 day (the total score of the UKU-SERS M, 8 [3; 11.75] vs M, 2 [1; 6]; p=0.034). The carriers of DRD2 rs1800497 reported a greater severity of antipsychotic-induced neurological disorders (UKU-SERS subscale score M, 1 [0; 2.25] vs M 0 [0; 1]; p=0.029).Conclusion. The polymorphic variants DRD2 rs1800497 and ABCB1 3435C>T were established to be significantly associated with the efficacy and safety of antipsychotics in adolescents with an acute psychotic episode.https://nnp.ima-press.net/nnp/article/view/1324pharmacogeneticsantipsychoticsadolescentsacute psychotic episodesafetyefficacy |
collection |
DOAJ |
language |
Russian |
format |
Article |
sources |
DOAJ |
author |
D. V. Ivashchenko S. Z. Khoang M. Kh. Tazagulova B. V. Makhmudova N. I. Buromskaya P. V. Shimanov R. V. Deitch I. V. Dorina M. I. Nastovich K. A. Akmalova A. A. Kachanova E. A. Grishina L. M. Savchenko Yu. S. Shevchenko D. A. Sychev |
spellingShingle |
D. V. Ivashchenko S. Z. Khoang M. Kh. Tazagulova B. V. Makhmudova N. I. Buromskaya P. V. Shimanov R. V. Deitch I. V. Dorina M. I. Nastovich K. A. Akmalova A. A. Kachanova E. A. Grishina L. M. Savchenko Yu. S. Shevchenko D. A. Sychev The polymorphic variants DRD2 rs1800497 and ABCB1 3435C>T are associated with antipsychotic safety parameters in adolescents with an acute psychotic episode: the results of a pilot study Nevrologiâ, Nejropsihiatriâ, Psihosomatika pharmacogenetics antipsychotics adolescents acute psychotic episode safety efficacy |
author_facet |
D. V. Ivashchenko S. Z. Khoang M. Kh. Tazagulova B. V. Makhmudova N. I. Buromskaya P. V. Shimanov R. V. Deitch I. V. Dorina M. I. Nastovich K. A. Akmalova A. A. Kachanova E. A. Grishina L. M. Savchenko Yu. S. Shevchenko D. A. Sychev |
author_sort |
D. V. Ivashchenko |
title |
The polymorphic variants DRD2 rs1800497 and ABCB1 3435C>T are associated with antipsychotic safety parameters in adolescents with an acute psychotic episode: the results of a pilot study |
title_short |
The polymorphic variants DRD2 rs1800497 and ABCB1 3435C>T are associated with antipsychotic safety parameters in adolescents with an acute psychotic episode: the results of a pilot study |
title_full |
The polymorphic variants DRD2 rs1800497 and ABCB1 3435C>T are associated with antipsychotic safety parameters in adolescents with an acute psychotic episode: the results of a pilot study |
title_fullStr |
The polymorphic variants DRD2 rs1800497 and ABCB1 3435C>T are associated with antipsychotic safety parameters in adolescents with an acute psychotic episode: the results of a pilot study |
title_full_unstemmed |
The polymorphic variants DRD2 rs1800497 and ABCB1 3435C>T are associated with antipsychotic safety parameters in adolescents with an acute psychotic episode: the results of a pilot study |
title_sort |
polymorphic variants drd2 rs1800497 and abcb1 3435c>t are associated with antipsychotic safety parameters in adolescents with an acute psychotic episode: the results of a pilot study |
publisher |
IMA-PRESS LLC |
series |
Nevrologiâ, Nejropsihiatriâ, Psihosomatika |
issn |
2074-2711 2310-1342 |
publishDate |
2020-10-01 |
description |
Children and adolescents are more likely than adults to experience adverse side effects when taking antipsychotics. Pharmacogenetic testing allows one to more accurately choose the initial dose of a drug. The genes of pharmacokinetic factors have been shown to be of high prognostic value for the safety of antipsychotics in adults.Patients and methods. The study enrolled 36 adolescents (58.3% male) (mean age, 14.83±1.84 years). All the patients took an antipsychotic. The follow-up lasted 28 days. On 14 and 28 days of treatment, its efficiency and safety were evaluated using the Children's Global Assessment Scale (CGAS), the Positive and Negative Syndrome Scale (PANSS), the Udvalg for Kliniske Undersњgelser Side Effects Rating Scale (UKU-SERS), the Simpson-Angus Scale (SAS), and the Barnes Akathisia Rating Scale (BARS). The patients were genotyped for CYP3A4*22, CYP3A5*3, CYP2D6*4, *9, *10, ABCB1 1236C>T, 2677G>T/A, 3435C>T, DRD2 rs1800497, DRD4 rs1800955, and HTR2A rs6313.Results and discussion. The decrease in the mean score of the PANSS subscale “Productive symptoms” was more pronounced in carriers of the DRD2 rs1800497 polymorphic variant (-6.5 [-10.25; -3.75] vs -3 [-6.5; -2 ] on 14 day (p=0.028) and (-11 [-13; -9.5] vs -5 [-9; -3.5] on 28 day (p=0.001) compared to baseline. The carriage of ABCB1 3435CT+TT was associated with worse tolerance to pharmacotherapy on 14 day (the total score of the UKU-SERS M, 8 [3; 11.75] vs M, 2 [1; 6]; p=0.034). The carriers of DRD2 rs1800497 reported a greater severity of antipsychotic-induced neurological disorders (UKU-SERS subscale score M, 1 [0; 2.25] vs M 0 [0; 1]; p=0.029).Conclusion. The polymorphic variants DRD2 rs1800497 and ABCB1 3435C>T were established to be significantly associated with the efficacy and safety of antipsychotics in adolescents with an acute psychotic episode. |
topic |
pharmacogenetics antipsychotics adolescents acute psychotic episode safety efficacy |
url |
https://nnp.ima-press.net/nnp/article/view/1324 |
work_keys_str_mv |
AT dvivashchenko thepolymorphicvariantsdrd2rs1800497andabcb13435ctareassociatedwithantipsychoticsafetyparametersinadolescentswithanacutepsychoticepisodetheresultsofapilotstudy AT szkhoang thepolymorphicvariantsdrd2rs1800497andabcb13435ctareassociatedwithantipsychoticsafetyparametersinadolescentswithanacutepsychoticepisodetheresultsofapilotstudy AT mkhtazagulova thepolymorphicvariantsdrd2rs1800497andabcb13435ctareassociatedwithantipsychoticsafetyparametersinadolescentswithanacutepsychoticepisodetheresultsofapilotstudy AT bvmakhmudova thepolymorphicvariantsdrd2rs1800497andabcb13435ctareassociatedwithantipsychoticsafetyparametersinadolescentswithanacutepsychoticepisodetheresultsofapilotstudy AT niburomskaya thepolymorphicvariantsdrd2rs1800497andabcb13435ctareassociatedwithantipsychoticsafetyparametersinadolescentswithanacutepsychoticepisodetheresultsofapilotstudy AT pvshimanov thepolymorphicvariantsdrd2rs1800497andabcb13435ctareassociatedwithantipsychoticsafetyparametersinadolescentswithanacutepsychoticepisodetheresultsofapilotstudy AT rvdeitch thepolymorphicvariantsdrd2rs1800497andabcb13435ctareassociatedwithantipsychoticsafetyparametersinadolescentswithanacutepsychoticepisodetheresultsofapilotstudy AT ivdorina thepolymorphicvariantsdrd2rs1800497andabcb13435ctareassociatedwithantipsychoticsafetyparametersinadolescentswithanacutepsychoticepisodetheresultsofapilotstudy AT minastovich thepolymorphicvariantsdrd2rs1800497andabcb13435ctareassociatedwithantipsychoticsafetyparametersinadolescentswithanacutepsychoticepisodetheresultsofapilotstudy AT kaakmalova thepolymorphicvariantsdrd2rs1800497andabcb13435ctareassociatedwithantipsychoticsafetyparametersinadolescentswithanacutepsychoticepisodetheresultsofapilotstudy AT aakachanova thepolymorphicvariantsdrd2rs1800497andabcb13435ctareassociatedwithantipsychoticsafetyparametersinadolescentswithanacutepsychoticepisodetheresultsofapilotstudy AT eagrishina thepolymorphicvariantsdrd2rs1800497andabcb13435ctareassociatedwithantipsychoticsafetyparametersinadolescentswithanacutepsychoticepisodetheresultsofapilotstudy AT lmsavchenko thepolymorphicvariantsdrd2rs1800497andabcb13435ctareassociatedwithantipsychoticsafetyparametersinadolescentswithanacutepsychoticepisodetheresultsofapilotstudy AT yusshevchenko thepolymorphicvariantsdrd2rs1800497andabcb13435ctareassociatedwithantipsychoticsafetyparametersinadolescentswithanacutepsychoticepisodetheresultsofapilotstudy AT dasychev thepolymorphicvariantsdrd2rs1800497andabcb13435ctareassociatedwithantipsychoticsafetyparametersinadolescentswithanacutepsychoticepisodetheresultsofapilotstudy AT dvivashchenko polymorphicvariantsdrd2rs1800497andabcb13435ctareassociatedwithantipsychoticsafetyparametersinadolescentswithanacutepsychoticepisodetheresultsofapilotstudy AT szkhoang polymorphicvariantsdrd2rs1800497andabcb13435ctareassociatedwithantipsychoticsafetyparametersinadolescentswithanacutepsychoticepisodetheresultsofapilotstudy AT mkhtazagulova polymorphicvariantsdrd2rs1800497andabcb13435ctareassociatedwithantipsychoticsafetyparametersinadolescentswithanacutepsychoticepisodetheresultsofapilotstudy AT bvmakhmudova polymorphicvariantsdrd2rs1800497andabcb13435ctareassociatedwithantipsychoticsafetyparametersinadolescentswithanacutepsychoticepisodetheresultsofapilotstudy AT niburomskaya polymorphicvariantsdrd2rs1800497andabcb13435ctareassociatedwithantipsychoticsafetyparametersinadolescentswithanacutepsychoticepisodetheresultsofapilotstudy AT pvshimanov polymorphicvariantsdrd2rs1800497andabcb13435ctareassociatedwithantipsychoticsafetyparametersinadolescentswithanacutepsychoticepisodetheresultsofapilotstudy AT rvdeitch polymorphicvariantsdrd2rs1800497andabcb13435ctareassociatedwithantipsychoticsafetyparametersinadolescentswithanacutepsychoticepisodetheresultsofapilotstudy AT ivdorina polymorphicvariantsdrd2rs1800497andabcb13435ctareassociatedwithantipsychoticsafetyparametersinadolescentswithanacutepsychoticepisodetheresultsofapilotstudy AT minastovich polymorphicvariantsdrd2rs1800497andabcb13435ctareassociatedwithantipsychoticsafetyparametersinadolescentswithanacutepsychoticepisodetheresultsofapilotstudy AT kaakmalova polymorphicvariantsdrd2rs1800497andabcb13435ctareassociatedwithantipsychoticsafetyparametersinadolescentswithanacutepsychoticepisodetheresultsofapilotstudy AT aakachanova polymorphicvariantsdrd2rs1800497andabcb13435ctareassociatedwithantipsychoticsafetyparametersinadolescentswithanacutepsychoticepisodetheresultsofapilotstudy AT eagrishina polymorphicvariantsdrd2rs1800497andabcb13435ctareassociatedwithantipsychoticsafetyparametersinadolescentswithanacutepsychoticepisodetheresultsofapilotstudy AT lmsavchenko polymorphicvariantsdrd2rs1800497andabcb13435ctareassociatedwithantipsychoticsafetyparametersinadolescentswithanacutepsychoticepisodetheresultsofapilotstudy AT yusshevchenko polymorphicvariantsdrd2rs1800497andabcb13435ctareassociatedwithantipsychoticsafetyparametersinadolescentswithanacutepsychoticepisodetheresultsofapilotstudy AT dasychev polymorphicvariantsdrd2rs1800497andabcb13435ctareassociatedwithantipsychoticsafetyparametersinadolescentswithanacutepsychoticepisodetheresultsofapilotstudy |
_version_ |
1721250512298311680 |